S

Seaport Therapeutics

Develops orally bioavailable antidepressants and anxiolytics

Associate Director, Regulatory Affairs

Regulatory & Quality (Life Sciences)Confirmed live in the last 24 hours
Full-timeBoston, MA, USA$180k - $205k

About the Job

Requirements

  • A bachelor's degree is required; an advanced degree in a scientific discipline is preferred.
  • At least 7 years of global regulatory affairs experience, including expertise in early development (Pre-IND/IND) and late-phase strategy for central nervous system therapies.
  • Relevant hands-on experience leading IND/CTA and/or NDA/MAA submissions.
  • Experience leading Pre-IND or INTERACT meetings and IND/CTA submissions for psychiatry/neurology programs.
  • Experience designing Phase II proof-of-concept studies with validated endpoints.
  • Experience preparing Phase III-ready protocols and health authority interactions, including FDA EOP2, scientific advice, and Pre-NDA.
  • Deep knowledge of global regulatory frameworks and electronic Common Technical Document (eCTD) submission standards.
  • Practical, applied fluency in FDA/EMA neuroscience guidelines and International Council for Harmonisation (ICH) standards.
  • Proficiency with publishing and document management tools such as Veeva, Smartsheet, and Office Timeline Pro.
  • Strong project management skills and a track record of driving regulatory deliverables in a fast-paced environment.
  • Exceptional attention to detail, collaboration, and communication skills.

Responsibilities

  • Provide strategic and operational regulatory guidance to internal clinical, nonclinical, chemistry, manufacturing and controls (CMC), and commercial teams.
  • Serve as the primary regulatory lead to the global project core team for assigned development programs.
  • Manage regulatory timelines and document workflows to ensure submission readiness and compliance.
  • Lead early interactions, including Pre-IND discussions, with global health authorities such as the FDA, EMA, and PMDA to align on preclinical packages, first-in-human protocols, and biomarker strategies for central nervous system therapies.
  • Partner with research and development teams to embed regulatory requirements into target product profiles and investigational plans from candidate nomination through post-marketing.
  • Design integrated early development strategic plans that connect preclinical data, including toxicology, pharmacology, and CMC, with Phase I/II clinical objectives and address psychiatry/neurology challenges such as blood-brain barrier delivery and placebo response mitigation.
  • Prepare risk-mitigated IND/CTA submissions.
  • Develop Phase II protocols with Go/No-Go criteria and strategies to de-risk psychiatry/neurology programs.
  • Prepare Phase III regulatory groundwork, including End-of-Phase II meeting packages, safety database planning, and alignment with ICH guidelines for multi-regional trials.
  • Contribute to NDA/MAA submission roadmaps to ensure late-phase clinical, nonclinical, and CMC data packages meet regional requirements for central nervous system therapies.
  • Support portfolio prioritization by balancing early-stage innovation with late-phase assets to optimize resource allocation and regulatory success.

Desired Qualifications

  • An advanced degree in a scientific discipline.

About the Company

Seaport Therapeutics

Develops orally bioavailable antidepressants and anxiolytics

Seaport Therapeutics develops new antidepressants and anxiolytics for neuropsychiatric disorders. Its products are designed to be orally bioavailable and to avoid first-pass metabolism while minimizing hepatotoxicity and other side effects. The company advances drug candidates through clinical trials and regulatory approval with the aim of commercialization, either directly or via partnerships and licensing with larger pharmaceutical companies. The team combines biotech industry experience to support development and execution. Unlike some peers, Seaport focuses on PK properties that improve oral bioavailability and safety, aiming for drugs that patients can take easily and with fewer liver-related risks. The overarching goal is to bring safe, effective neuropsychiatric medications to patients by progressing through development to market, leveraging partnerships to scale.

Company size
51-200
Company stage
IPO
Headquarters
Boston, MA
Founded
2024

Recently Posted Jobs

Explore more opportunities at Seaport Therapeutics

See more jobs